Representative stakeholders were consulted on how they felt access to pediatric tuberculosis (TB) drugs could be improved. A key recommendation is the development of new child-friendly, adequately dosed formulations with a good shelf life in all climate zones. There is also an urgent need to improve the diagnosis and reporting of children with TB. Manufacturers of pediatric TB medications are to be incentivized through improved coordination among all stakeholders, with streamlined regulatory approvals and increased consumer education on drug and regimen guidelines. Finally, pooled procurement is advised to ensure sustained market supply against affordable prices.
Usherenko, I.; Basu Roy, U.; Mazlish, S.; Lui, S.; Benkoscki, L.; Coutts, D.; Epstein, S.; Qian, M.; Rafiq, S.; Scott, C. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions. International Journal of Tuberculosis and Lung Disease (2015) 19 (12) 23-31. [DOI: 10.5588/ijtld.15.0479]